Wordt geladen...

Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity

BACKGROUND: Bortezomib (Bz) is a proteasome inhibitor that directly targets antibody-producing plasma cells. We recently reported the first randomized control trial that evaluated the effects of Bz in patients with systemic lupus erythematosus (SLE). In that study, we demonstrated that Bz treatment...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Arthritis Res Ther
Hoofdauteurs: Ikeda, Tomoko, Fujii, Hiroshi, Nose, Masato, Kamogawa, Yukiko, Shirai, Tsuyoshi, Shirota, Yuko, Ishii, Tomonori, Harigae, Hideo
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioMed Central 2017
Onderwerpen:
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5553803/
https://ncbi.nlm.nih.gov/pubmed/28800777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-017-1397-7
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!